Fortress Biotech, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Segment Information (Tables)

Segment Information (Tables)

12 Months Ended

Dec. 31, 2020

The Company operates in two reportable segments, Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development. The accounting policies of the Company’s segments are the same as those described in Note 2. The following tables summarize, for the periods indicated, operating results from continued operations by reportable segment:


			Pharmaceutical
			and
	Dermatology		Biotechnology
($ in thousands)	Products		Product
Year Ended December 31, 2020	Sales		Development		Consolidated
Net revenue	$	44,531	$	1,068	$	45,599
Direct cost of goods		(14,594)		—		(14,594)
Sales and marketing costs		(17,384)		—		(17,384)
Research and development		—		(64,109)		(64,109)
General and administrative		(4,716)		(39,066)		(43,782)
Other expense		(697)		(7,882)		(8,579)
Income tax expense		(96)		(40)		(136)
Segment income (loss)	$	7,044	$	(110,029)	$	(102,985)
Segment assets
Intangible assets, net		14,629		—		14,629
Tangible assets		30,843		283,362		314,205
Total segment assets	$	45,472	$	283,362	$	328,834


			Pharmaceutical
			and
	Dermatology		Biotechnology
($ in thousands)	Products		Product
Year Ended December 31, 2019	Sales		Development		Consolidated
Net revenue	$	34,921	$	1,708	$	36,629
Direct cost of goods		(10,532)		—		(10,532)
Sales and marketing costs		(17,120)		—		(17,120)
Research and development		—		(81,326)		(81,326)
General and administrative		(2,556)		(35,914)		(38,470)
Other income		—		9,159		9,159
Segment income (loss)	$	4,713	$	(106,373)	$	(101,660)
Segment assets
Intangible assets, net		7,377		—		7,377
Tangible assets		19,946		199,099		219,045
Total segment assets	$	27,323	$	199,099	$	226,422